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systemic embolism in AF, and acute coronary syn-
drome, in CAD. In the latter, percutaneous coro-
nary intervention (PCI) with stent implantation 
is the standard of care.6 It is also widely used in 
patients with stable CAD to relieve symptoms of 
myocardial ischemia due to flow-limiting coronary 
disease.6-8 Patients undergoing PCI are at risk of 
stent thrombosis, particularly in the case of first-
generation drug-eluting stents.9 Antiproliferative 
substances profoundly inhibit the reparative re-
sponse to arterial injury and delay endothelializa-
tion, thus leading to persistent prothrombotic and 
proinflammatory reactions as well as neointimal 
atherosclerotic change (neoatherosclerosis).10,11
Pathogenesis of thrombosis in atrial fibrillation and 
coronary artery disease The pathogenesis of 
thrombus development in AF and CAD is slightly 
Introduction Atrial fibrillation (AF) and coronary 
artery disease (CAD) often coexist. The pattern 
of this comorbidity has not changed significant-
ly over the last decade.1-5 In 2 recent registries 
(the EURObservational Research Programme AF 
[EORP-AF] Pilot General Registry and PREven-
tion oF thromboembolic events—European Reg-
istry in AF [PREFER in AF]), which together col-
lected prospective data from 16 participating Eu-
ropean countries (over 10000 patients), approx-
imately 20% to 35% of the patients were found 
to have CAD.2,3 This was consistent across differ-
ent types of AF (eg, new onset, paroxysmal, per-
sistent, and permanent).2 Up to half of these pa-
tients have had myocardial infarction (MI) or un-
dergone coronary revascularization or both.2,3
Both AF and CAD confer an increased risk of 
acute thrombotic complications, that is, stroke or 
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ABSTRACT
Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist. Both conditions confer an increased 
risk of acute thrombotic complications. However, the pathogenesis of thrombus development in AF and 
CAD is different. Coagulation activation is the main pathway in AF, and platelet activation is the hallmark 
of coronary thrombosis. Antithrombotic prophylaxis is essential in both conditions.
In patients with AF undergoing percutaneous coronary intervention (PCI), a combination of oral antico-
agulation and antiplatelet therapy is required, which elevates the risk of major bleeding. This has to be 
balanced against the risk of stroke and stent thrombosis.
In the first part of the present review, the prerequisites for antithrombotic management in AF patients 
undergoing PCI are discussed. We cover the epidemiology of concomitant presentation of AF and CAD 
as well as differences in the pathogenesis of thrombus formation in both conditions. We evaluate data 
regarding a variety of antithrombotic regimens including triple therapy in line with stroke and bleeding 
risk assessment.
Overall, triple therapy is often warranted but should be for the shortest possible duration. Although much 
of the current guidance comes from observational data, well designed, adequately powered randomized 
clinical trials are emerging to further inform practice in this challenging area.
REVIEW ARTICLE
Patients with atrial fibrillation undergoing 
percutaneous coronary intervention 
Current concepts and concerns: part I
Mikhail S. Dzeshka1,2, Richard A. Brown1, Gregory Y.H. Lip1,3
1  University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom
2  Grodno State Medical University, Grodno, Belarus
3  Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark
Ре
по
зи
то
ри
й Г
рГ
М
У
POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2015; 125 (1-2)74
antithrombotic therapy in AF patients undergo-
ing PCI have proved difficult.24,26-28
The first part of the present review discusses 
some concerns related to combination antithrom-
botic therapy in patients with AF who need PCI 
in the acute or chronic setting (ie, balancing the 
risk of ischemic and hemorrhagic complications) 
as well as opportunities to reduce the risks, for 
example, with a combination of OAC and sin-
gle antiplatelet therapy in lieu of dual antiplate-
let therapy.
Concomitant atrial fibrillation and coronary artery 
disease New-onset AF, particularly if uncon-
trolled, may exacerbate preexisting CAD by caus-
ing an abrupt increase in myocardial oxygen de-
mand, leading to ischemia that during sinus 
rhythm remains compensated. In turn, ion cur-
rents are particularly sensitive to oxygen supply, 
and hypoxia may cause ectopic flow in the atria 
and generate AF.29,30
In several studies, either new-onset or pre-ex-
isting AF was shown to have a negative impact on 
prognosis in patients with CAD treated with PCI 
(TABLE 1).31-35 AF may result in progressive deterio-
ration of systolic function if heart rate is not con-
trolled. It confers an increased stroke risk and re-
quires OAC (with or without antiplatelets), which, 
in turn, is associated with a risk of hemorrhage. 
Despite adjustment for possible confounders, 
AF appeared to be an independent predictor of 
death, stroke, and other adverse events. Baseline 
characteristics of AF patients were usually differ-
ent from patients in sinus rhythm (eg, older age, 
worse renal function, lower left ventricular ejec-
tion fraction). Hence, it is not always obvious 
different (FIGURE). Clot structure is known to be af-
fected by the velocity of blood flow and wall shear 
rates, which vary widely along blood vessels of dif-
ferent caliber and type and were found to reach 
the highest levels in the arteries, particularly at 
sites of stenotic lesions. Coagulation activation 
against the background of low flow, blood stasis, 
and increased expression of procoagulant factors, 
leading to fibrin-rich thrombus formation is the 
main pathway in AF, and platelet activation at 
sites of vascular injury under high flow resulting 
in platelet-rich thrombus development is a hall-
mark of coronary thrombosis.12-15
This results in differences to antithrombotic 
prevention, which is essential in both conditions. 
While patients with nonvalvular AF and 1 addi-
tional stroke risk factor (ie, the vast majority of 
AF population) clearly benefit from oral antico-
agulation (OAC),16-20 notwithstanding a sufficient 
protective effect of OAC in stable CAD,21 those 
with ACS or stable CAD but undergoing stent im-
plantation require antiplatelet therapy (FIGURE).6
Thus, AF patients undergoing PCI require a 
period of treatment with OAC and either single 
or dual antiplatelet therapy to inhibit both path-
ways, the combination of which increases the 
risk of major bleeding.22-25 This must be weighed 
against the risk of stroke and stent thrombosis. 
Recent studies have focused on finding the ide-
al combination of antithrombotic therapy while 
maintaining efficacy and safety for patients.22,23
Current guidelines consist mainly of an ex-
pert opinion based on observational data, and 
prospective randomized clinical trials (RCTs) 
are warranted to inform modern clinical prac-
tice.22,23 As a result, attempts to standardize 
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Antithrombotic prevention, of any descrip-
tion is associated with an increased risk of hem-
orrhage. The HAS-BLED score (TABLE 2)39 is rec-
ommended for the assessment of risk of major 
bleeding with the score of 3 as a cut-off for high 
risk.16,22 It is important to note that a HAS-BLED 
score of 3 or higher alone should not be used as a 
reason to withhold OAC. An elevated HAS-BLED 
score rather highlights the requirement for clos-
er monitoring (international normalized ratio 
[INR] in case of anticoagulation with VKAs, kid-
ney function when NOACs are used) and correc-
tion of modifiable bleeding risk factors, for ex-
ample, removal of unnecessary concomitant an-
tiplatelet therapy / nonsteroidal anti-inflamma-
tory drugs, reduction in excessive alcohol intake, 
tight blood pressure control.36,37
The HAS-BLED score is simple, practical, and 
has been well-validated in multiple cohorts; how-
ever, in AF patients undergoing PCI, combined 
multiple antithrombotic drugs are likely to inter-
fere with its predictive ability. Thus, it should be 
used for the assessment of baseline bleeding risk 
to define the most appropriate combination and 
duration of antithrombotic therapy.16,22
Once combination therapy has been started, 
the HAS-BLED score appears to be less useful 
and shows inconsistent performance. In a ret-
rospective analysis of a cohort with ACS who re-
ceived OAC in addition to dual antiplatelet ther-
apy due to various indications (predominant-
ly AF and apical akinesia), the HAS-BLED score 
reliably predicted spontaneous bleeding events 
with a c statistic of 0.67 (95% CI, 0.54–0.79).41 
More contemporary data from the AFCAS regis-
try showed no statistically significant difference 
in hemorrhage between distinct risk strata as 
classified via the HAS-BLED score as well as other 
whether AF directly affects the clinical course of 
CAD or merely reflects a poorer baseline state.
In any scenario, AF forces amendments in 
the management of CAD patients, with the an-
tithrombotic therapy for thromboprophylaxis per-
haps being the most challenging area.
Stroke and bleeding risk assessment The impact 
of AF on stroke risk depends on the presence of 
other vascular risk factors, and appropriate risk 
stratification is important.36,37 The CHA2DS2-VASc 
score38 (TABLE 2) is now recommended by the Eu-
ropean and other guidelines for decision mak-
ing with respect to OAC in patients with non-
valvular AF.16,22
Vascular disease in the CHA2DS2-VASc score 
includes peripheral artery disease, aortic plaque, 
and prior MI or coronary revascularization. 
Hence, patients with AF undergoing PCI are at a 
risk of stroke and require OAC with either a well-
adjusted vitamin K antagonist (VKA) or one of 
novel OACs.
The CHA2DS2-VASc score reliably predicts 
all-cause mortality (hazard ratio [HR], 1.16; 95% 
confidence interval [CI], 1.02–1.32) and major ad-
verse cardiac and cerebrovascular events (MAC-
CE, defined as composite of all-cause death, MI, 
target vessel revascularization, definite/proba-
ble stent thrombosis, transient ischemic attack 
or stroke; HR, 1.17; 95% CI, 1.06–1.28) among AF 
patients undergoing PCI in the prospective obser-
vational, multicentre registry including patients 
with AF who are referred for the PCI AFCAS reg-
istry (Management of Patients With Atrial Fibril-
lation Undergoing Coronary Artery Stenting).40 
An important finding from this registry was that 
only approximately 10% of AF patients were at 
a low risk for stroke prior to registry entrance.40
TABLE 2 Stroke and bleeding risk stratification with the CHA2DS2-VASc38 and HAS-BLED scores39
CHA2DS2-VASca Score HAS-BLEDb Score
congestive heart failure/LV dysfunction 1 hypertension (systolic blood pressure 
>160 mmHg)
1
hypertension 1 abnormal renal or liver function 1 or 2
age ≥75 years 2 stroke 1
diabetes mellitus 1 bleeding tendency or predisposition 1
stroke/TIA/TE 2 labile INRs (if on warfarin) 1
vascular disease (prior MI, PAD, or aortic 
plaque)
1 age (eg, >65, frail condition) 1
aged 65–74 years 1 drugs (eg, concomitant antiplatelet or 
NSAIDs) or alcohol excess/abuse
1 or 2
sex category (ie, female) 1
maximum score 9 9
a CHA2DS2-VASc: heart failure (moderate-to-severe left ventricular systolic dysfunction refer to left ventricular 
ejection fraction ≤40% or recent decompensated heart failure requiring hospitalization), hypertension, age ≥75 years, 
diabetes, stroke/TIA, vascular disease (specifically, myocardial infarction, complex aortic plaque, and peripheral artery 
disease), age 65–74 years, female sex 
b HAS-BLED: uncontrolled hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, 
labile INR, elderly patients (eg, age >65 years, frail condition), drugs (eg, antiplatelet, NSAIDs)/excessive alcohol
Abbreviations: INR, international normalized ratio; LV, left ventricular; NSAIDs, nonsteroidal anti-inflammatory drugs; 
TE, thromboembolism; TIA, transient ischemic attack; PAD, peripheral artery disease; others, see TABLE 1
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Studies on triple therapy in AF patients un-
dergoing PCI are mostly observational, often ret-
rospective, single-centre, and hence underpow-
ered to reveal a difference in event rates between 
groups with different strategies of antithrombot-
ic therapy. The proportion of AF and ACS patients 
included, event definitions and follow-up dura-
tion also varied widely. In the absence of robust 
evidence finding the equilibrium between the risk 
of serious bleeding on the one hand, and stroke, 
recurrent cardiac ischemia, stent thrombosis on 
the other, is particularly challenging.
There have been plenty of such studies weigh-
ing pros and cons of triple antithrombotic thera-
py against other antithrombotic regimens (Supple-
mentary material online, Table S1) as well as a few 
meta-analyses (TABLE 3) that have been published.
Dual antiplatelet therapy with aspirin and clop-
idogrel is inferior to triple antithrombotic thera-
py in AF patients undergoing PCI particularly for 
ischemic stroke. Strokes in AF are usually severe 
and associated with poorer outcomes compared 
with non-AF-related strokes. Thus, OAC cannot 
be omitted. OAC was beneficial even in patients 
with high bleeding risk (HAS-BLED score, ≥3) 
and octogenarians: subsets of patients in whom 
OAC is often withheld by clinicians for fear of 
bleeding complications, particularly intracrani-
al hemorrhage, even in chronically anticoagulat-
ed patients with no need for combination anti-
thrombotic therapy.51,56
The choice between triple therapy and OAC 
plus single antiplatelet is less well-defined. The 
WOEST trial (What is the Optimal antiplatE-
let and anticoagulant therapy in patients with 
oral anticoagulation and coronary StenTing) was 
open-label, intention-to-treat RCT, in which tri-
ple therapy was compared with double therapy 
of OAC and clopidogrel (thus omitting aspirin).58 
At 1-year follow-up, lower bleeding and mortality 
rates were revealed in the warfarin-plus-clopido-
grel arm compared with the triple-therapy arm 
(HR, 0.36; 95% CI, 0.26–0.50, and HR, 0.39; 95% 
CI, 0.16–0.93, respectively) with no significant 
differences in the rate of thrombotic events.58 
However, the WOEST trial had many limitations. 
First, the lower bleeding rate with dual thera-
py was driven by a reduction of minor bleeding 
available bleeding risk assessment schemes (eg, 
HEMORR2HAGES, ATRIA, etc.).
42,43 This is not 
unexpected since the HAS-BLED score was de-
rived and validated in cohorts of “stable” antico-
agulated AF patients.36,37
ACS-specific risk scores such as the GRACE 
2.0 ACS Risk Calculator44-46 for predicting death 
or death/MI following an initial ACS, CRUSADE 
score47,48 for bleeding risk assessment, and stent 
thrombosis scores49,50 may be used; however, they 
have not been validated in AF cohorts and do not 
impact on decision making with respect to anti-
thrombotic management in AF patients under-
going PCI.
Overall, the vast majority of AF patients un-
dergoing PCI have a high risk both for stroke and 
major bleeding.51 Thus, antithrombotic therapy 
in this group of patients has to carefully balance 
thromboembolism versus bleeding.
Triple antithrombotic therapy: is there an alterna-
tive? Triple antithrombotic therapy (namely 
OAC in combination with dual antiplatelet ther-
apy) for patients with AF undergoing PCI devel-
oped as a result of OAC is indicated for AF pa-
tients, and dual antiplatelet therapy is indicated 
for ACS patients.7,8,16,22,24 It is also supported by 
the pathology of clot formation and is generally 
deemed to be appropriate but until recently has 
not been tested in an RCT.12-15
However, adding antiplatelet agents on top 
of OAC inevitably results in elevation of bleed-
ing risk.52-54 In a large analysis from the nation-
wide Danish registry including over 80,000 AF 
patients, HRs of fatal or nonfatal bleeding were 
as follows: 1.66 (95% CI, 1.34–2.04) for dual an-
tiplatelet therapy; 1.83 (95% CI, 1.72–1.96) for 
warfarin and aspirin; 3.08 (95% CI, 2.32–3.91) 
for warfarin and clopidogrel, and 3.70 (95% 
CI, 2.89–4.76) for triple therapy versus warfa-
rin monotherapy as a reference.52 Consistent re-
sults were obtained in the meta-analysis includ-
ed 18 studies with patients receiving triple ther-
apy after PCI and stenting: odds ratio (OR), 2.38; 
95% CI, 1.05–5.38 at 30 days, and 2.87; 95% CI, 
1.47–5.62 at 6 months compared with dual anti-
platelet therapy.53
TABLE 3 Meta-analyses on efficacy and safety of triple antithrombotic therapy versus dual antiplatelet therapy in patients with atrial fibrillation 
undergoing percutaneous coronary intervention with stent implantation
Reference Number of 
studies 
included
Clinical outcomes, odds ratio (95% confidence interval)
MACE ischemic stroke MI all-cause death major bleeding
Gao et al. 201171 9 NR 0.29 (0.15–0.58) 0.84 (0.57–1.23) 1.20 (0.63–2.27) 2.00 (1.41–2.83)
Saheb et al. 201372 10 0.76 (0.54–1.07)a 0.27 (0.13–0.57) 0.57 (0.22–1.50) NR 1.47 (1.22–1.78)
Zhao et al. 201173 9 0.60 (0.42–0.86)b 0.38 (0.12–1.22) NR 0.59 (0.39–0.90) 2.12 (1.05–4.29)
a cardiac death, acute myocardial infarction, stent thrombosis, or target lesion revascularization 
b death, myocardial infarction/reinfarction, stent thrombosis, target vessel revascularization, stroke and bleeding
Abbreviations: MACE, major adverse cardiovascular events (composite of death, myocardial infarction/reinfarction, stent thrombosis, target vessel 
revascularization, stroke, and bleeding); others, see TABLE 1
Ре
по
зи
то
ри
й
Гр
ГМ
У
POLSKIE ARCHIWUM MEDYCYNY WEWNĘTRZNEJ 2015; 125 (1-2)78
coronary death, MI, and major bleeding togeth-
er with similar efficacy for stroke prevention and 
no increase in mortality, OAC plus clopidogrel ap-
pears to be the most attractive option.65
In summary, based on available evidence, tri-
ple antithrombotic therapy in patients with AF 
and CAD undergoing PCI with stenting is a “nec-
essary evil”, where necessity is determined by an 
elevated risk of ischemic and embolic events with 
“lighter” antithrombotic combinations (eg, dual 
antiplatelet therapy or OAC plus single antiplate-
let agent, particularly clopidogrel) and elevated 
bleeding risk is the main threat. Thus, attempts 
should be made to shorten exposure to such a reg-
imen as much as possible depending on the clini-
cal scenario, type of stent, baseline bleeding and 
stroke risk.77 Also, while dual antiplatelet thera-
py appeared to be the least effective in this group 
of patients, as a lower bleeding rate is usually ac-
companied by a higher stroke rate, the choice be-
tween triple therapy and OAC plus clopidogrel re-
mains a controversial issue.
Conclusions The trade-off between bleeding, em-
bolic complications, and coronary thrombosis rep-
resents a complex and challenging area. Evidence 
informing the management of AF patients under-
going PCI is gradually increasing but we are still 
lacking large randomized trials testing various 
combinations of antithrombotic therapy. Thus 
far, triple antithrombotic therapy is warranted 
to prevent thrombotic and embolic events at the 
cost of increased risk of bleeding. Intentions to 
reduce its duration or replace with OAC combined 
with single antiplatelet therapy have been made, 
and they are deemed appropriate, particularly in 
a subset of patients with moderate stroke and/or 
high bleeding risk. Therefore, baseline stroke and 
bleeding risk assessment are important for the fi-
nal judgment as well as clinical setting.
Supplementary material online Supplementary 
material online is available with the online ver-
sion of the paper at www.pamw.pl.
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STRESZCZENIE
Migotanie przedsionków (atrial fibrillation – AF) i choroba wieńcowa (coronary artery disease – CAD) 
często współistnieją. Oba stany niosą zwiększone ryzyko ostrych powikłań zakrzepowych, jednak pato-
geneza powstawania zakrzepu w AF i w CAD jest odmienna. W AF głównym szlakiem jest aktywacja 
kaskady krzepnięcia, natomiast w zakrzepicy wieńcowej kluczową rolę odgrywa aktywacja płytek. W obu 
stanach podstawowe znaczenie ma profilaktyka przeciwzakrzepowa.
U chorych z AF poddawanych przezskórnej interwencji wieńcowej (percutaneous coronary intervention – 
PCI) konieczne jest kojarzenie doustnych antykoagulantów i leków przeciwpłytkowych, co zwiększa ryzyko 
poważnego krwawienia. Trzeba je odnieść do ryzyka udaru i zakrzepicy w stencie.
W części 1. niniejszego przeglądu przeanalizowano wymogi leczenia przeciwzakrzepowego u chorych z AF 
poddawanych PCI. Omówiono epidemiologię współwystępowania AF i CAD, a także różnice w patogenezie 
zakrzepicy w obu stanach. Poddano ocenie dane dotyczące różnych wariantów leczenia przeciwzakrze-
powego, w tym terapii potrójnej, w aspekcie oceny ryzyka krwawienia i udaru.
Ogólnie – terapia potrójna jest często uzasadniona, ale powinna być stosowana jak najkrócej. Większość 
aktualnych zaleceń opiera się na danych obserwacyjnych, ale pojawiają się dobrze zaplanowane, o od-
powiedniej mocy badania z randomizacją, które pozwolą nam poszerzyć wiedzę w tej trudnej dziedzinie.
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Table S1 Summary of studies comparing triple antithrombotic therapy with dual antiplatelet therapy or oral anticoagulation plus single antiplatelet therapy
Study N Design Follow-up Population Compared regimes Clinical outcomesa
major bleeding minor bleeding any bleeding death CV death MI TVR stent thrombosis stroke SE MAC(C)E overall
Bernard et al. 201355 417 retrospective, 
single-center
650 days AF, PCI-S ACS 61.9% OAC/no OAC at discharge 4.3/3.4 NR NR 5.2/11.9 NR MI 5.2/3.4 NR 5.2/9.1i 5.2/9.1 i 23.7/32.5d
0.58 (0.32-1.05)
Caballero et al. 201356 604 retrospective, 
two-center
17 months AF, PCI-S
ACS 75.8%
octogenarians 15.7%
OAC/no OAC at discharge 20.9/21.2 9.7/15.4 NR 22.2/44.4d
3.75 (0.97-14.53)
NR 20.6/25.0 NR NR NR 8.9/18.9 28.9/58.3c
4.30 (1.26–14.56)
Dąbrowska et al. 
201357
104 prospective, 
single-center
1 year AF, PCI-S
ACS NR
TT/DAPT 11.1/6.9 27.8/10.3 38.9/17.2 0/13.8 NR 2.2/19.4c NR 0/0 NR NR NR
Dewilde et al. 201358 573 rct, open-label, 
multicenter
1 year PCI-S
AF 69%
ACS NR
TT/OAC+clopidogrel 5.6/3.2 NR 44.4/19.4c
0.36 (0.26–0.50)
6.3/2.5c
0.39 (0.16–0.93)
2.5/1.1 3.4/11.1b 6.7/7.2 3.2/1.4 2.8/0.7d
0.25 (0.05–1.17)
NR NR
Fosbol et al. 201359 1648 retrospective, 
multicenter
1 year AF, NSTEMI, PCI-S TT/DAPT 15.5/12.8d
1.29 (0.96-1.74)
NR NR 12.9/13.3 NR 4.6/3.2 NR NR 1.6/2.2 NR 19.4/20.6
Gao et al. 201060 622 prospective, 
single-center
1 year AF, DES
ACS 14.1%
TT/DAPT/OAC+ATe 2.9/1.8/2.5 8.8/3.3/5.0c 11.8/5.1/7.4c 4.4/9.0/5.8 NR 6.3/6.8 3.7/4.5/4.1 0.7/0.9/1.7 0.7/3.6/0.8d NR 8.8/20.1/14.9c
Gilard et al. 200961 359 prospective, 
multicenter
1 year PCI-S
AF 69.1%
ACS NR
TT/DAPT 5.6/2.1c NR 18.4/16.0 8/5.6 4.0/2.6 2.9/5.4/5.8 NR 1.6/1.7 0.8/3 0.8/0 NR
Ho et al. 201362 602 retrospective, 
single-center
2 years AF, PCI-S
ACS NR
TT/DAPT 24.5/20.4 NR NR 1.6/5.3
(CHADS2 ≤2)
11.4/10.0 
(CHADS2>2)
NR 5.0/4.3b NR NR 2.2/1.8 NR NR
Mutuberria et al. 
201363
640 prospective, 
multicenter
1 year AF, PCI-S
ACS NR
TT vs DAPT 5.3/0 NR NR 8.4/1.3 c 8.4/0 c NR NR NR NR 1.1/1.3 13.7/9.3
Karjalainen et al. 
200764
478 retrospective, 
multicenter
1 year PCI-S
AF 35.1%
ACS 53.8%
TT/DAPT 8.2/2.6c
3.3 (1.3–8.6)
NR NR 8.7/1.8c
5.3 (1.8–16.0)
NR NR 11.0/7.5 4.1/1.3 3.2/2.2d
3.2 (0.8–12.1)
NR 21.9/11.0c
2.3 (1.3–3.8)
Lamberts et al. 201365 12165 retrospective, 
nationwide
1 year AF, PCI
MI 77.2%
TT/DAPT/OAC+ASA/
OAC+clopidogrelf
14.3c /6.9/9.7c /10.9c
2.08 (1.64–2.65)
1.44 (1.14–1.83)
1.63 (1.15–2.30)
NR NR 8.9c /17.5/15.6/7.1c
0.61 (0.47–0.77)
0.54 (0.35–0.76)
2.5c /5.3/3.9/1.2g
0.58 (0.36–0.92)
10.0/4.8 c
2.2 (1.0–4.7)
NR NR 4.1c /6.3/5.6c /2.8c
0.67 (0.46–0.98)
0.81 (0.61–1.08) 0.51 (0.28–0.95)
NR NR
Rossini et al. 200866 204 prospective, 
single-center
18 months PCI-S
AF 66.6%
ACS 78.9%
TT/DAPT 2.9/2 7.8/2.9 10.8/4.9 2.9/1.0 1/1 16.2d /21.3/17.7c /9.6c,h
0.83 (0.68–1.00)
0.78 (0.66–0.91)
0.56 (0.40–0.79)
1/2.9 1/2 1/2 NR 5.8/4.9
Rubboli et al. 201267 632 prospective, 
multicenter
1 year PCI-S
AF 58%
ACS 63%
TT/DAPT/OAC+ASA 5.0/2.0/2.6 NR NR 9.9/8.5/10.2 NR 2/2 12.3/10.3/11.9 2.7/1.7/2.0 1.0/4.1/1.1d 1.8/2.8/0d NR
Ruiz-Nodar et al. 
200868
426 retrospective, 
two-center
594 days AF, PCI-S
ACS 83.9%
TT/DAPT 14.9/9.0 12.6/9.0 NR 17.8/27.8c NR 11.3/5.5/9.3d 7.1/8.4 1.2/1.3 NR 1.7/6.9 c 26.5/38.7
4.9 (2.17–11.09)
Ruiz-Nodar et al. 
201251
420 retrospective, 
two-center
1 year AF, PCI-S
ACS 86.4%
HAS-BLED ≥3
OAC/no OAC at discharge 11.8/4.0 c
3.03 (1.24–7.38)
NR NR 9.3/20.1c
0.45 (0.26–0.78)
NR 6.5/10.4 NR NR NR NR 13.0/26.4c
0.48 (0.29–0.77)
Sambola et al. 200969 405 prospective, 
multicenter
6 months PCI-S
AF 67.6%
ACS NR
TT/DAPT/OAC+ATe 4.3/1.2/6.5 11.2/2.5/6.5c 15.5/3.7/13c 6.8/1.2/10.9d 4.3/0/8.7c NR 3.6/0/4.3 4.0/0/8.7c 0.3/1.2/2.2 i 0.3/1.2/2.2 i 7.9/1.2/15.2a
Smith et al. 201241 318 etrospective, 
single center
1 year ACS, PCI-S
AF 19.8%
TT/DAPT 13.4/3.8c NR NR 4.5/2.5 NR NR NR NR 1.9/1.9 0/0 NR
Uchida et al. 201070 575 prospective, 
single-center
459 days DES
AF 5%
ACS 39.1%
TT/DAPT 20/2.7c
8.02 (3.34-19.15)
20/9.9c 40/12.8c 8/3.4 NR 3.8/1.3b 14/7.4d 0/0 4/1.1 NR 22/12c
1.74 (0.91-3.35)d
a rate of events in groups, %; odd or hazard ratio (95% confidence interval) for significant associations when available; b acute coronary syndrome; c significant difference in event rates; d trend toward between-groups difference; e over 80% of patients in OAC plus single antiplatelet group were receiving clopidogrel; f TT and OAC plus single antiplatelet therapy vs DAPT; g coronary 
death or fatal stroke; h MI/coronary death; i stroke or systemic embolism
For a list of references, see the main article.
Abbreviations: ACS, acute coronary syndrome; AT, single antiplatelet therapy; AF, atrial fibrillation; ASA, acetylsalicylic acid; CHADS2, congestive heart failure, hypertension, age, diabetes, stroke; CV, cardiovascular; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; MAC(C)E, major adverse cardiac (and cerebral) events; MI, myocardial infarction; NR, not reported; NSTEMI, non-ST-
segment elevation myocardial infarction; OAC, oral anticoagulation; PCI(-S), percutaneous coronary intervention (with stenting); RCT, randomized controlled trial; SE, systemic embolism; TT, triple antithrombotic therapy; TVR, target vessel revascularizationРе
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